Inhibikase director granted 155,000 stock options

Inhibikase Therapeutics director Roberto Bellini received a grant of stock options for 155,000 shares of Common Stock.

Rhea-AI Filing Summary

Inhibikase Therapeutics director Roberto Bellini received a grant of stock options for 155,000 shares of Common Stock. The options have an exercise price of $1.91 per share and expire on June 26, 2036. Following this grant, he holds 155,000 options directly.

The options will vest on the earlier of June 26, 2027 or the day before the next annual meeting of stockholders, as long as he continues to serve as a director through that date. This is a compensation-related award, not an open-market share purchase or sale.

Insider Trade Summary

Grant/Award: 155,000 shares

Grant/Award 1 txn

Insider Bellini Roberto

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	155,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 155,000 contracts (Direct)

Footnotes (1)

1. F1. The options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.

Key Figures

Options granted: 155,000 options Exercise price: $1.91 per share Expiration date: June 26, 2036 +2 more

5 metrics

Options granted 155,000 options Stock Option (Right to Buy) grant to director

Exercise price $1.91 per share Exercise price for the granted stock options

Expiration date June 26, 2036 Option expiration for the 155,000 granted options

Total options after grant 155,000 options Total derivative securities held following transaction

Vesting date June 26, 2027 Latest vesting date, or earlier day before next annual meeting

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, Grant, award, or other acquisition, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "1.9100""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2036-06-26T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

annual meeting of stockholders financial

"The options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Inhibikase Therapeutics (IKT) report for Roberto Bellini?

Inhibikase Therapeutics reported that director Roberto Bellini received a grant of stock options for 155,000 shares. These options are compensation, not an open-market trade, and give him the right to buy common stock at a fixed exercise price in the future.

How many Inhibikase Therapeutics (IKT) stock options were granted to Roberto Bellini and at what price?

Roberto Bellini was granted 155,000 stock options linked to Inhibikase common shares. Each option has an exercise price of $1.91 per share, meaning he can buy shares at that price once the options vest and before they expire.

When do Roberto Bellini’s Inhibikase (IKT) stock options vest and expire?

The options vest on the earlier of June 26, 2027 or the day before Inhibikase’s next annual stockholder meeting. They expire on June 26, 2036. Vesting requires Bellini to continue serving as a director through the applicable vesting date.

Is Roberto Bellini buying or selling Inhibikase (IKT) shares in this Form 4?

This Form 4 shows a grant of stock options, not a market purchase or sale of shares. It is recorded as an acquisition under code A, representing a compensation award that gives future rights to buy stock at a fixed exercise price.

How many Inhibikase (IKT) derivative securities does Roberto Bellini hold after this grant?

After the transaction, Roberto Bellini holds 155,000 stock options directly. Each option is exercisable for one share of Inhibikase common stock at an exercise price of $1.91, subject to vesting conditions and the June 26, 2036 expiration date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/30/2026 - 04:05 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bellini Roberto

(Last) (First) (Middle)

1000 N. WEST STREET, SUITE 1200

(Street)

WILMINGTON DELAWARE 19801

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Inhibikase Therapeutics, Inc. [ IKT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.91	06/26/2026		A		155,000		(1)	06/26/2036	Common Stock	155,000	$0	155,000	D

Explanation of Responses:

1. The options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.

	/s/ Mark Iwicki, attorney-in-fact	06/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)